{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:07:05Z","timestamp":1792951625354,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["17104820"],"award-info":[{"award-number":["17104820"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intratumoral heterogeneity in metastatic cancers complicates effective treatment, as distinct tumor subclones display varying drug sensitivities and metastatic capabilities, interacting through mechanisms that remain poorly understood. In this study, we utilized an isogenic ovarian cancer cell pair distinguished by differential \u03b2-catenin signaling: non-metastatic (NM) cells with low \u03b2-catenin and highly metastatic (HM) cells with elevated \u03b2-catenin signaling. Co-engrafting NM and HM cells synergistically enhances peritoneal metastasis compared to either subclone alone. Immunohistochemical analysis revealed a mosaic \u03b2-catenin expression in mixed tumors, recapitulating the heterogeneity observed in clinical ovarian cancer cases. Notably, both NM cells and \u03b2-catenin-knockout HM cells exhibited an intrinsic senescence-associated secretory phenotype (SASP), mechanistically driven by Hippo\/YAP signaling, which was suppressed by \u03b2-catenin in HM cells. This phenotype in turn facilitated the metastatic dissemination of \u03b2-catenin-high subclones through paracrine signaling. Importantly, mixed in vivo tumors were more susceptible to treatment with fisetin, a senolytic agent, and YAP inhibition, leading to marked reduction in metastatic burden. Overall, our findings demonstrate the pre-existence of senescence-like tumor cells in untreated conditions and reveal a novel cooperative mechanism in which \u03b2-catenin heterogeneity facilitates ovarian cancer progression through SASP-mediated subclonal interactions. These results provide a basis for targeted therapeutic strategies to disrupt intratumoral communication and improve treatment outcomes in metastatic ovarian cancer.<\/jats:p>","DOI":"10.1038\/s41419-026-08737-7","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:05:08Z","timestamp":1776938708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Subclonal \u03b2-catenin\/YAP signaling heterogeneity accelerates ovarian cancer metastasis through a senescence-associated secretory phenotype"],"prefix":"10.1038","volume":"17","author":[{"given":"Sally K. Y.","family":"To","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie S. W.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Ling","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J. X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-9838","authenticated-orcid":false,"given":"Philip P. C.","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-6475","authenticated-orcid":false,"given":"Alice S. T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"8737_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell. 2020;37:471\u201384.","journal-title":"Cancer Cell"},{"key":"8737_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394.","journal-title":"Nat Rev Clin Oncol"},{"key":"8737_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41556-018-0236-7","volume":"20","author":"DA Lawson","year":"2018","unstructured":"Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour heterogeneity and metastasis at single-cell resolution. Nat Cell Biol. 2018;20:1349\u201360.","journal-title":"Nat Cell Biol"},{"key":"8737_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.trecan.2018.02.003","volume":"4","author":"HM Levitin","year":"2018","unstructured":"Levitin HM, Yuan J, Sims PA. Single-cell transcriptomic analysis of tumor heterogeneity. Trends Cancer. 2018;4:264\u20138.","journal-title":"Trends Cancer"},{"key":"8737_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature13187","volume":"508","author":"AS Cleary","year":"2014","unstructured":"Cleary AS, Leonard TL, Gestl SA, Gunther EJ. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature. 2014;508:113\u20137.","journal-title":"Nature"},{"key":"8737_CR6","doi-asserted-by":"publisher","first-page":"eadh4184","DOI":"10.1126\/sciadv.adh4184","volume":"9","author":"BJ Hershey","year":"2023","unstructured":"Hershey BJ, Barozzi S, Orsenigo F, Pompei S, Iannelli F, Kamrad S, et al. Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect. Sci Adv. 2023;9:eadh4184.","journal-title":"Sci Adv"},{"key":"8737_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41556-019-0346-x","volume":"21","author":"M Janiszewska","year":"2019","unstructured":"Janiszewska M, Tabassum DP, Casta\u00f1o Z, Cristea S, Yamamoto KN, Kingston NL, et al. Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019;21:879\u201388.","journal-title":"Nat Cell Biol"},{"key":"8737_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.trecan.2021.01.009","volume":"7","author":"S Bhattacharya","year":"2021","unstructured":"Bhattacharya S, Mohanty A, Achuthan S, Kotnala S, Jolly MK, Kulkarni P, et al. Group behavior and emergence of cancer drug resistance. Trends Cancer. 2021;7:323\u201334.","journal-title":"Trends Cancer"},{"key":"8737_CR9","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"8737_CR10","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.xcrm.2023.101055","volume":"4","author":"P Cunnea","year":"2023","unstructured":"Cunnea P, Curry EW, Christie EL, Nixon K, Kwok CH, Pandey A, et al. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: implications for surgical and clinical outcomes. Cell Rep Med. 2023;4:101055.","journal-title":"Cell Rep Med"},{"key":"8737_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccell.2020.01.003","volume":"37","author":"Z Hu","year":"2020","unstructured":"Hu Z, Artibani M, Alsaadi A, Wietek N, Morotti M, Shi T, et al. The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells. Cancer Cell. 2020;37:226\u2013.e7.","journal-title":"Cancer Cell"},{"key":"8737_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47271-y","volume":"15","author":"E Denisenko","year":"2024","unstructured":"Denisenko E, de Kock L, Tan A, Beasley AB, Beilin M, Jones ME, et al. Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones. Nat Commun. 2024;15:2860.","journal-title":"Nat Commun"},{"key":"8737_CR13","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1038\/onc.2012.290","volume":"32","author":"WK Chau","year":"2013","unstructured":"Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt\/\u03b2-catenin-ATP-binding cassette G2 signaling. Oncogene. 2013;32:2767\u201381.","journal-title":"Oncogene"},{"key":"8737_CR14","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1038\/onc.2017.185","volume":"36","author":"SKY To","year":"2017","unstructured":"To SKY, Mak ASC, Eva Fung YM, Che CM, Li SS, Deng W, et al. \u03b2-catenin downregulates Dicer to promote ovarian cancer metastasis. Oncogene. 2017;36:5927\u201338.","journal-title":"Oncogene"},{"key":"8737_CR15","doi-asserted-by":"publisher","first-page":"e2103230","DOI":"10.1002\/advs.202103230","volume":"9","author":"SKY To","year":"2022","unstructured":"To SKY, Tang MKS, Tong Y, Zhang J, Chan KKL, Ip PPC, et al. A selective \u03b2-catenin-metadherin\/CEACAM1-CCL3 axis mediates metastatic heterogeneity upon tumor-macrophage interaction. Adv Sci. 2022;9:e2103230.","journal-title":"Adv Sci"},{"key":"8737_CR16","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","volume":"51","author":"M Katoh","year":"2017","unstructured":"Katoh M. Canonical and non-canonical Wnt signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming and targeted therapy and tumor plasticity. Int J Oncol. 2017;51:1357\u201369.","journal-title":"Int J Oncol"},{"key":"8737_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20110112","volume":"437","author":"MV Barbolina","year":"2011","unstructured":"Barbolina MV, Burkhalter RJ, Stack MS. Diverse mechanisms for activation of Wnt signaling in the ovarian tumor microenvironment. Biochem J. 2011;437:1\u201312.","journal-title":"Biochem J"},{"key":"8737_CR18","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/onc.2014.178","volume":"34","author":"S Condello","year":"2015","unstructured":"Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, et al. \u03b2-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene. 2015;34:2297\u2013308.","journal-title":"Oncogene"},{"key":"8737_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2018.01.053","volume":"22","author":"VD Gonzalez","year":"2018","unstructured":"Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, et al. Commonly occurring cell subsets in high-grade serous ovarian tumors identified by single-cell mass cytometry. Cell Rep. 2018;22:1875\u201388.","journal-title":"Cell Rep"},{"key":"8737_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4161\/19336918.2014.972761","volume":"9","author":"D Neelakantan","year":"2015","unstructured":"Neelakantan D, Drasin DJ, Ford HL. Intratumoral heterogeneity: clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adh Migr. 2015;9:265\u201376.","journal-title":"Cell Adh Migr"},{"key":"8737_CR21","doi-asserted-by":"publisher","first-page":"111283","DOI":"10.1016\/j.celrep.2022.111283","volume":"40","author":"H Tari","year":"2022","unstructured":"Tari H, Kessler K, Trahearn N, Werner B, Vinci M, Jones C, et al. Quantification of spatial subclonal interactions enhancing the invasive phenotype of pediatric glioma. Cell Rep. 2022;40:111283.","journal-title":"Cell Rep"},{"key":"8737_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","volume":"123","author":"CE Ford","year":"2020","unstructured":"Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. Br J Cancer. 2020;123:9\u201316.","journal-title":"Br J Cancer"},{"key":"8737_CR23","doi-asserted-by":"publisher","first-page":"101939","DOI":"10.1016\/j.tranon.2024.101939","volume":"44","author":"YK Carmi","year":"2024","unstructured":"Carmi YK, Agbarya A, Khamaisi H, Farah R, Shechtman Y, Korobochka R, et al. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells. Transl Oncol. 2024;44:101939.","journal-title":"Transl Oncol"},{"key":"8737_CR24","doi-asserted-by":"publisher","first-page":"43267","DOI":"10.18632\/oncotarget.6530","volume":"6","author":"G Carbotti","year":"2015","unstructured":"Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6:43267\u201380.","journal-title":"Oncotarget"},{"key":"8737_CR25","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1200\/JCO.1998.16.5.1861","volume":"16","author":"AG Zeimet","year":"1998","unstructured":"Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, M\u00fcller-Holzner E, et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol. 1998;16:1861\u20138.","journal-title":"J Clin Oncol"},{"key":"8737_CR26","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1101\/gad.343129.120","volume":"34","author":"J Birch","year":"2020","unstructured":"Birch J, Gil J. Senescence and the SASP: many therapeutic avenues. Genes Dev. 2020;34:1565\u201376.","journal-title":"Genes Dev"},{"key":"8737_CR27","first-page":"4101","volume":"22","author":"L Jiang","year":"2020","unstructured":"Jiang L, Li J, Zhang C, Shang Y, Lin J. YAP\u2011mediated crosstalk between the Wnt and Hippo signaling pathways (Review). Mol Med Rep. 2020;22:4101\u20136.","journal-title":"Mol Med Rep"},{"key":"8737_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"Verteporfin In Photodynamic Therapy Study Group.","year":"2001","unstructured":"Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541\u201360.","journal-title":"Am J Ophthalmol"},{"key":"8737_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15280","volume":"8","author":"X Zhang","year":"2017","unstructured":"Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, et al. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 2017;8:15280.","journal-title":"Nat Commun"},{"key":"8737_CR30","doi-asserted-by":"publisher","first-page":"9009","DOI":"10.3390\/molecules27249009","volume":"27","author":"AH Rahmani","year":"2022","unstructured":"Rahmani AH, Almatroudi A, Allemailem KS, Khan AA, Almatroodi SA. The potential role of fisetin, a flavonoid in cancer prevention and treatment. Molecules. 2022;27:9009.","journal-title":"Molecules"},{"key":"8737_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/procel\/pwaf019","volume":"16","author":"Y Cai","year":"2025","unstructured":"Cai Y, Guan Z, Tong Y, Zhao W, Zhang J, Peng L, et al. Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis. Protein Cell. 2025;16:602\u20138.","journal-title":"Protein Cell"},{"key":"8737_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ceb.2007.02.007","volume":"19","author":"R Fodde","year":"2007","unstructured":"Fodde R, Brabletz T. Wnt\/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007;19:150\u20138.","journal-title":"Curr Opin Cell Biol"},{"key":"8737_CR33","doi-asserted-by":"publisher","first-page":"eabg1850","DOI":"10.1126\/sciadv.abg1850","volume":"7","author":"Q Wu","year":"2021","unstructured":"Wu Q, Guo J, Liu Y, Zheng Q, Li X, Wu C, et al. YAP drives fate conversion and chemoresistance of small cell lung cancer. Sci Adv. 2021;7:eabg1850.","journal-title":"Sci Adv"},{"key":"8737_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1126\/science.1199010","volume":"332","author":"T Heallen","year":"2011","unstructured":"Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. 2011;332:458\u201361.","journal-title":"Science"},{"key":"8737_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP\/TAZ incorporation in the \u03b2-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157\u201370.","journal-title":"Cell"},{"key":"8737_CR36","doi-asserted-by":"publisher","first-page":"11730","DOI":"10.1074\/jbc.M111.327767","volume":"287","author":"WM Konsavage Jr","year":"2012","unstructured":"Konsavage WM Jr, Kyler SL, Rennoll SA, Jin G, Yochum GS. Wnt\/\u03b2-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells. J Biol Chem. 2012;287:11730\u20139.","journal-title":"J Biol Chem"},{"key":"8737_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","volume":"147","author":"J Tao","year":"2014","unstructured":"Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, et al. Activation of \u03b2-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147:690\u2013701.","journal-title":"Gastroenterology"},{"key":"8737_CR38","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/0008-5472.CAN-20-2801","volume":"81","author":"HM Quinn","year":"2021","unstructured":"Quinn HM, Vogel R, Popp O, Mertins P, Lan L, Messerschmidt C, et al. YAP and \u03b2-Catenin cooperate to drive oncogenesis in basal breast cancer. Cancer Res. 2021;81:2116\u201327.","journal-title":"Cancer Res"},{"key":"8737_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"8737_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria M, O\u2019Leary MN, Chang J, Shao L, Liu S, Alimirah F, et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 2017;7:165\u201376.","journal-title":"Cancer Discov"},{"key":"8737_CR41","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013;75:685\u2013705.","journal-title":"Annu Rev Physiol"},{"key":"8737_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic M, Fan DNY, Belenki D, D\u00e4britz JHM, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96\u2013100.","journal-title":"Nature"},{"key":"8737_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc2772","volume":"10","author":"M Collado","year":"2010","unstructured":"Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10:51\u201357.","journal-title":"Nat Rev Cancer"},{"key":"8737_CR44","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrd.2017.116","volume":"16","author":"BG Childs","year":"2017","unstructured":"Childs BG, Gluscevic M, Baker DJ, Laberge RM, Marquess D, Dananberg J, et al. Senescent cells: an emerging target for diseases of ageing. Nat Rev Drug Discov. 2017;16:718\u201335.","journal-title":"Nat Rev Drug Discov"},{"key":"8737_CR45","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1093\/jnci\/djq364","volume":"102","author":"JA Ewald","year":"2010","unstructured":"Ewald JA, Desotelle JA, Wilding G, Jarrard DF. Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010;102:1536\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"8737_CR46","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1038\/s12276-021-00717-5","volume":"53","author":"SS Park","year":"2021","unstructured":"Park SS, Choi YW, Kim JH, Kim HS, Park TJ. Senescent tumor cells: an overlooked adversary in the battle against cancer. Exp Mol Med. 2021;53:1834\u201341.","journal-title":"Exp Mol Med"},{"key":"8737_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc3960","volume":"15","author":"NE Sharpless","year":"2015","unstructured":"Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer. 2015;15:397\u2013408.","journal-title":"Nat Rev Cancer"},{"key":"8737_CR48","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/cancers12020296","volume":"12","author":"M Paku\u0142a","year":"2020","unstructured":"Paku\u0142a M, Ma\u0142y E, Uruski P, Witucka A, Bogucka M, Jaroszewska N, et al. Deciphering the molecular mechanism of spontaneous senescence in primary epithelial ovarian cancer cells. Cancers. 2020;12:296.","journal-title":"Cancers"},{"key":"8737_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-01023-y","volume":"15","author":"S Rutecki","year":"2022","unstructured":"Rutecki S, Szulc P, Paku\u0142a M, Uruski P, Radziemski A, Naumowicz E, et al. Pro-cancerogenic effects of spontaneous and drug-induced senescence of ovarian cancer cells in vitro and in vivo: a comparative analysis. J Ovarian Res. 2022;15:87.","journal-title":"J Ovarian Res"},{"key":"8737_CR50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14:576\u201390.","journal-title":"Nat Rev Endocrinol"},{"key":"8737_CR51","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.tcb.2020.07.002","volume":"30","author":"M Borghesan","year":"2020","unstructured":"Borghesan M, Hoogaars WMH, Varela-Eirin M, Talma N, Demaria M. A senescence-centric view of aging: Implications for longevity and disease. Trends Cell Biol. 2020;30:777\u201391.","journal-title":"Trends Cell Biol"},{"key":"8737_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11762","volume":"7","author":"MK Ruhland","year":"2016","unstructured":"Ruhland MK, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun. 2016;7:11762.","journal-title":"Nat Commun"},{"key":"8737_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1242\/jcs.01635","volume":"118","author":"S Parrinello","year":"2005","unstructured":"Parrinello S, Coppe JP, Krtolica A, Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005;118:485\u201396.","journal-title":"J Cell Sci"},{"key":"8737_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41514-024-00168-y","volume":"10","author":"EA O\u2019Sullivan","year":"2024","unstructured":"O\u2019Sullivan EA, Wallis R, Mossa F, Bishop CL. The paradox of senescent-marker positive cancer cells: challenges and opportunities. NPJ Aging. 2024;10:41.","journal-title":"NPJ Aging"},{"key":"8737_CR55","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ncb3397","volume":"18","author":"M Hoare","year":"2016","unstructured":"Hoare M, Ito Y, Kang TW, Weekes MP, Matheson NJ, Patten DA, et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat Cell Biol. 2016;18:979\u201392.","journal-title":"Nat Cell Biol"},{"key":"8737_CR56","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ebiom.2018.09.015","volume":"36","author":"MJ Yousefzadeh","year":"2018","unstructured":"Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18\u201328.","journal-title":"EBioMedicine"},{"key":"8737_CR57","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1039\/C7FO01898C","volume":"9","author":"A Farsad-Naeimi","year":"2018","unstructured":"Farsad-Naeimi A, Alizadeh M, Esfahani A, Darvish Aminabad E. Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food Funct. 2018;9:2025\u201331.","journal-title":"Food Funct"},{"key":"8737_CR58","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.3390\/nu15214686","volume":"15","author":"A Markowska","year":"2023","unstructured":"Markowska A, Antoszczak M, Kacprzak K, Markowska J, Huczy\u0144ski A. Role of fisetin in selected malignant neoplasms in women. Nutrients. 2023;15:4686.","journal-title":"Nutrients"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08737-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:04:01Z","timestamp":1780625041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8737"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08737-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The use of human materials was approved by the Institutional Review Board of The University of Hong Kong, and written informed consent was obtained. Animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research at The University of Hong Kong (No. 5259-19) and were conducted in compliance with the Animals (Control of Experiments) Ordinance of Hong Kong.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"539"}}